NCT07102940 2026-02-20
Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
George Washington University
Phase 2 Not yet recruiting
Clinical Trials
13 trialsNCT07107217 2025-08-17
Camella
Blokhin's Russian Cancer Research Center
Phase 2 Not yet recruiting
NCT00516724 2025-04-11
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
AstraZeneca
Phase 1 Completed
NCT03168880 2025-04-09
TNBC
Tata Memorial Hospital
Phase 3 Active not recruiting
NCT03609047 2024-01-24
Appalaches
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT04137653 2021-07-20
Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
Shengjing Hospital
Phase 3 Recruiting
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT01314833 2020-05-19
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
Fudan University
Phase 3 Completed
NCT00689156 2018-04-05
READ
Danish Breast Cancer Cooperative Group
Phase 3 Completed
NCT00912444 2016-11-22
NATT
Shanghai Jiao Tong University School of Medicine
Phase 3 Terminated
NCT02207361 2015-12-22
Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 4 Unknown
NCT00919880 2014-08-15
Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer
Peking University
Phase 2 Completed
NCT01203267 2010-09-16
Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Completed